古塞奇尤单抗在患有中度至重度活动性克罗恩病的儿科参与者中的研究 (MACARONI-23)
抑制 IL-23 通路 p19 以确定小儿克罗恩病疗效的 3 期、多中心、随机平台研究
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Study Contact
- 电话号码:844-434-4210
- 邮箱:Participate-In-This-Study1@its.jnj.com
学习地点
-
-
-
Beersheba、以色列、84101
- 招聘中
- Soroka University Medical Center
-
Be’er Ya‘aqov、以色列、70300
- 招聘中
- Shamir Medical Center Assaf Harofeh
-
Jerusalem、以色列、9103102
- 招聘中
- Shaare Zedek Medical Center
-
Jerusalem、以色列、9124001
- 招聘中
- Hadassah Medical Center
-
Petah Tikva、以色列、4920235
- 招聘中
- Schneider Children's Medical Center
-
Rehovot、以色列、761001
- 招聘中
- Kaplan Medical Center
-
-
-
-
Nova Scotia
-
Halifax、Nova Scotia、加拿大、B3K 6R8
- 招聘中
- Iwk Health Centre
-
-
Ontario
-
London、Ontario、加拿大、N6A 5W9
- 招聘中
- London Health Sciences Centre Victoria Hospital
-
Toronto、Ontario、加拿大、M5G 1X8
- 招聘中
- Hospital For Sick Children
-
-
-
-
-
Vienna、奥地利、1090
- 招聘中
- AKH - Medizinische Universitat Wien
-
-
-
-
-
Campinas、巴西、13060-904
- 招聘中
- Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro
-
Curitiba、巴西、80250-060
- 招聘中
- Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro
-
Goiânia、巴西、74605-020
- 招聘中
- Universidade Federal de Goias - Hospital das Clinicas da UFG
-
Porto Alegre、巴西、90035-074
- 招聘中
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Porto Alegre、巴西、90035-007
- 招聘中
- Hospital De Clinicas De Porto Alegre
-
Vitória、巴西、29040-091
- 招聘中
- Centro de Ciencias e Saude da Universidade Federal do Espirito Santo-Nucleo de Doencas Infecciosas
-
Votuporanga、巴西、100000
- 招聘中
- INTEGRAL Pesquisa e Ensino
-
-
-
-
-
Alessandria、意大利、15121
- 招聘中
- A.O. Santi Antonio e Biagio e Cesare Arrigo
-
Bergamo、意大利、24127
- 招聘中
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
-
Bologna、意大利、40124
- 招聘中
- Ospedale Bellaria, U.O.Cardiologia Az. USL di Bologna
-
Florence、意大利、50139
- 招聘中
- Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
-
Milan、意大利、20154
- 招聘中
- Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale dei Bambini Vittore Buzzi
-
Roma、意大利、161
- 招聘中
- AOU Policlinico Umberto I
-
-
-
-
-
Nordbyhagen、挪威、1474
- 招聘中
- Akershus Universitetssykehus HF
-
Oslo、挪威、424
- 招聘中
- Oslo University Hospital
-
Tromsø、挪威、9038
- 招聘中
- Universitetssykehuset Nord-Norge HF
-
Trondheim、挪威、7030
- 招聘中
- St. Olavs Hospital
-
-
-
-
-
Hirosaki、日本、036-8563
- 招聘中
- Hirosaki University Hospital
-
Kagoshima、日本、890-8544
- 招聘中
- Kagoshima University Hospital
-
Kashiwa-shi、日本、277-0871
- 招聘中
- Tsujinaka Hospital Kashiwanoha
-
Kobe、日本、650 0017
- 招聘中
- Kobe University Hospital
-
Saga、日本、849-8501
- 招聘中
- Saga University Hospital
-
Sendai、日本、989-3126
- 招聘中
- Miyagi Childrens Hospital
-
Setagaya Ku、日本、157 8535
- 招聘中
- National Center for Child Health and Development
-
Tokyo、日本、113-8431
- 招聘中
- Juntendo University Hospital
-
Tsu、日本、514 8507
- 招聘中
- Mie University Hospital
-
Ube、日本、755-8505
- 招聘中
- Yamaguchi University Hospital
-
Yokohama、日本、232-0024
- 招聘中
- Yokohama City University Medical Center
-
Yokohama、日本、230-8765
- 招聘中
- Saiseikai Yokohamashi Tobu Hospital
-
-
-
-
-
Brussels、比利时、1090
- 招聘中
- Universitair Ziekenhuis Brussel
-
Brussels、比利时、1200
- 招聘中
- Cliniques Universitaires Saint Luc
-
Ghent、比利时、9000
- 招聘中
- Universitair Ziekenhuis Gent
-
Leuven、比利时、3000
- 招聘中
- UZ Leuven
-
-
-
-
-
Amiens、法国、80054
- 招聘中
- CHU Amiens-Hopital Nord
-
Lille、法国、59037
- 招聘中
- Hôpital Jeanne de FLANDRE, CHRU LILLE
-
Paris、法国、75019
- 招聘中
- Hôpital Robert Debré
-
Paris、法国、75015
- 招聘中
- Hôpital Necker - Enfants Malades
-
-
-
-
-
Rzeszów、波兰、35-302
- 招聘中
- Korczowski Bartosz Gabinet Lekarski
-
Warsaw、波兰、04 501
- 招聘中
- WIP Warsaw IBD Point Profesor Kierkus
-
Warsaw、波兰、04 730
- 招聘中
- Instytut Pomnik Centrum Zdrowia
-
-
-
-
-
Nedlands、澳大利亚、6009
- 招聘中
- Perth Children's Hospital
-
South Brisbane、澳大利亚、4101
- 招聘中
- Mater Hospital Brisbane
-
Westmead、澳大利亚、2145
- 招聘中
- The Children's Hospital at Westmead
-
-
-
-
California
-
Los Angeles、California、美国、90048
- 招聘中
- Cedars Sinai Medical Center
-
-
Connecticut
-
Hartford、Connecticut、美国、06106
- 招聘中
- Connecticut Children's Medical Center
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- 招聘中
- Emory University
-
Atlanta、Georgia、美国、30342
- 招聘中
- Children's Center for Digestive Health Care
-
-
Indiana
-
Indianapolis、Indiana、美国、46202-5225
- 招聘中
- Riley Hospital for Children
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- 招聘中
- Boston Childrens Hospital
-
-
New Jersey
-
Morristown、New Jersey、美国、07960
- 招聘中
- Goryeb Children's Hospital
-
-
New York
-
New York、New York、美国、10029
- 招聘中
- Icahn School of Medicine at Mount Sinai
-
New York、New York、美国、10032
- 招聘中
- Columbia University Medical Center
-
New York、New York、美国、10021-5663
- 招聘中
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
-
-
Ohio
-
Dayton、Ohio、美国、45404
- 招聘中
- The Children's Medical Center of Dayton
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- 招聘中
- Children's Hospital of Philadelphia
-
-
Texas
-
Fort Worth、Texas、美国、76104
- 招聘中
- Cook Childrens Medical Center
-
-
Vermont
-
Colchester、Vermont、美国、05446
- 招聘中
- University of Vermont Medical Center
-
-
-
-
-
Glasgow、英国、G51 4TF
- 招聘中
- Royal Hospital for Sick Children
-
London、英国、WC1N 3JH
- 招聘中
- Great Ormond Street Hospital
-
Manchester、英国、M13 9WL
- 招聘中
- Royal Manchester Children's Hospital
-
Manchester、英国、M13 9WL
- 招聘中
- Nowgen Centre, Research and Innovation
-
Oxford、英国、OX3 9DU
- 招聘中
- John Radcliffe Hospital
-
Sheffield、英国、S10 2TH
- 招聘中
- Sheffield Children's Hospital
-
-
-
-
-
Rotterdam、荷兰、3015 GD
- 招聘中
- Erasmus Medisch Centrum
-
-
-
-
-
Braga、葡萄牙、4710-243
- 招聘中
- Hospital de Braga
-
Lisbon、葡萄牙、1649-035
- 招聘中
- Centro Hospitalar de Lisboa Norte Hospital Santa Maria
-
Porto、葡萄牙、4200-319
- 招聘中
- Centro Hospitalar de Sao Joao E.P.E.
-
-
-
-
-
Córdoba、西班牙、14004
- 招聘中
- Hosp Reina Sofia
-
Sabadell、西班牙、8208
- 招聘中
- Corporacio Sanitari Parc Tauli
-
Valencia、西班牙、46026
- 招聘中
- Hosp. Univ. I Politecni La Fe
-
-
-
-
-
Busan、韩国、48108
- 招聘中
- Inje University Haeundae Paik Hospital
-
Daegu、韩国、41404
- 招聘中
- Kyungpook National University Chilgok Hospital
-
Seoul、韩国、03080
- 招聘中
- Seoul National University Hospital
-
Seoul、韩国、06351
- 招聘中
- Samsung Medical Center
-
Seoul、韩国、120-752
- 招聘中
- Severance Hospital Yonsei University Health System
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
- Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=] 30)
- Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
- Participants must have a history of inadequate response, loss of response, or intolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV corticosteroids, or biologic therapy/JAK inhibitor therapy; OR have a history of corticosteroid dependence; OR have a history of inadequate response to exclusive enteral nutrition (EEN)
Exclusion Criteria:
- Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery.
- Participants must not have an abscess
- Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Open-label induction phase: Guselkumab Intravenously (IV)
Participants will receive guselkumab dose IV based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
其他名称:
Guselkumab will be administered intravenously.
其他名称:
|
|
实验性的:Open-label induction phase: Guselkumab Subcutaneously (SC)
Participants will receive guselkumab dose SC based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
其他名称:
Guselkumab will be administered intravenously.
其他名称:
|
|
实验性的:Double-blind maintenance phase: Guselkumab SC Dose Regimen 1
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
其他名称:
Guselkumab will be administered intravenously.
其他名称:
|
|
实验性的:Double-blind Maintenance Phase: Guselkumab SC Dose Regimen 2
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
其他名称:
Guselkumab will be administered intravenously.
其他名称:
|
|
实验性的:Open-label maintenance phase: Guselkumab SC
Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
其他名称:
Guselkumab will be administered intravenously.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants with Clinical Remission at Week 52
大体时间:Week 52
|
Percentage of participants with clinical remission at Week 52 will be assessed. Clinical remission is defined as pediatric Crohn's Disease activity index (PCDAI) less than or equal to (<=) 10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response at Week 52
大体时间:Week 52
|
Percentage of participants who achieve endoscopic response at Week 52 will be assessed. Endoscopic response is defined as greater than or equal to (>=) 50 percent (%) reduction (global) and greater than (>) 50% reduction (U.S specific) from simplified endoscopic score-Crohn's Disease (SES-CD) score at baseline. |
Week 52
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants with Clinical Response at Week 12
大体时间:Week 12
|
Percentage of participants with clinical response at Week 12 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 12
|
|
Percentage of Participants with Clinical Response at Week 52
大体时间:Week 52
|
Percentage of participants with clinical response at Week 52 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 52
|
|
Percentage of Participants with Clinical Remission at Week 12
大体时间:Week 12
|
Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 12
|
|
Percentage of Participants with Endoscopic Remission at Week 52
大体时间:Week 52
|
Percentage of participants with endoscopic remission at Week 52 will be assessed. Endoscopic remission is defined as SES-CD total score <=4 and at least a 2-point reduction from baseline and no subscore >1. |
Week 52
|
|
Percentage of Participants with Corticosteroid-free Remission at Week 52
大体时间:Week 52
|
Percentage of participants with corticosteroid-free remission at Week 52 will be assessed. Corticosteroid-free remission is defined as PCDAI score <=10 at Week 52 and not receiving corticosteroids for at least 90 days before Week 52. |
Week 52
|
|
Percentage of Participants with Sustained Clinical Remission at Weeks 12, 24, and 52
大体时间:Weeks 12, 24, and 52
|
Percentage of participants with sustained clinical remission at Weeks 12, 24, and 52 will be assessed. Sustained clinical remission is defined as PCDAI <=10 at Weeks 12, 24, and 52. |
Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical remission by Patient-Reported Outcome (PRO-2)
大体时间:Week 12 and/or Week 52
|
Percentage of participants with clinical remission by PRO-2 will be assessed. Clinical remission by PRO-2 is defined as stool frequency (SF) <=3 and abdominal pain (AP) <=1 and no worsening of SF and AP from baseline. |
Week 12 and/or Week 52
|
|
Serum Concentration of Guselkumab During Induction Phase
大体时间:From Week 0 to Week 12
|
Serum concentrations of guselkumab will be assessed. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive immunoassay method. |
From Week 0 to Week 12
|
|
Trough Plasma Concentration (Ctrough) of Guselkumab During Maintenance Phase
大体时间:At Weeks 16, 24, 36, 48 and 52
|
Ctrough is defined as the serum concentration of guselkumab immediately prior (pre-dose) to the next drug administration. |
At Weeks 16, 24, 36, 48 and 52
|
|
Change from Baseline in Body Weight at Weeks 12, 24, and 52
大体时间:Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight Percentiles at Weeks 12, 24, and 52
大体时间:Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight z-scores at Weeks 12, 24, and 52
大体时间:Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height at Weeks 12, 24, and 52
大体时间:Baseline, Weeks 12, 24, and 52
|
Change from baseline in height at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Percentiles at Weeks 12, 24, and 52
大体时间:Baseline, Weeks 12, 24, and 52
|
Change from baseline in height percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height z-scores at Weeks 12, 24, and 52
大体时间:Baseline, Weeks 12, 24, and 52
|
Change from baseline in height z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Velocity at Weeks 12, 24, and 52
大体时间:Baseline, Weeks 12, 24, and 52
|
Change from baseline in height velocity at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical Remission
大体时间:Week 52
|
Percentage of participants with clinical remission who were assigned to guselkumab dose regimen 1 and did not receive rescue therapy at Week 52 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response
大体时间:Week 52
|
Percentage of participants who achieve endoscopic response who were assigned to q4w maintenance therapy and did not receive rescue therapy at Week 52 will be assessed. Endoscopic response is defined as >=50% reduction (global) and >50% reduction (U.S specific) from SES-CD score at baseline. |
Week 52
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:Up to Week 64
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important. |
Up to Week 64
|
合作者和调查者
调查人员
- 研究主任:Clinical Trial、Janssen Research & Development, LLC
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- CR109212
- 2021-006282-37 (EudraCT编号)
- CNTO1959PBCRD3007 (其他标识符:Janssen Research & Development, LLC)
- 2023-504735-41-00 (注册表标识符:EUCT number)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.